XBiotech(US:XBIT) Prnewswireยท2025-02-04 21:20Core Viewpoint - Pomerantz LLP is investigating claims on behalf of investors of XBiotech Inc. regarding potential securities fraud or unlawful business practices by the company and its officers [1][2]. Group 1: Company Developments - On December 23, 2024, XBiotech announced a pause in its phase 2 rheumatoid arthritis program after its candidate, Natrunix, failed to meet its primary endpoint, citing "substantial irregularities" that complicate the interpretation of findings [2]. - Following the announcement, XBiotech's stock price experienced a significant decline during intraday trading on the same day [2]. Group 2: Legal Context - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for the rights of victims of securities fraud and corporate misconduct [3].